Allison Avrich Ciesla, Josephine Mak, Lauren E. Roper, Katherine E. Fleming-Dutra, Zachary R. Smith, Ryan E. Wiegand, Amadea Britton, Joseph Miller, Ruth Link-Gelles
{"title":"二价 mRNA 疫苗在预防无症状 SARS-CoV-2 感染中的效果--增加社区接受检测计划的机会,美国,2023 年 1 月至 9 月。","authors":"Allison Avrich Ciesla, Josephine Mak, Lauren E. Roper, Katherine E. Fleming-Dutra, Zachary R. Smith, Ryan E. Wiegand, Amadea Britton, Joseph Miller, Ruth Link-Gelles","doi":"10.1111/irv.70038","DOIUrl":null,"url":null,"abstract":"<div>\n \n \n <section>\n \n <h3> Background</h3>\n \n <p>On September 2, 2022, bivalent COVID-19 mRNA vaccines, were recommended to address reduced effectiveness of COVID-19 monovalent vaccines during SARS-CoV-2 Omicron variant predominance.</p>\n </section>\n \n <section>\n \n <h3> Methods</h3>\n \n <p>Using national pharmacy-based SARS-CoV-2 testing program data from January 15 to September 11, 2023, this test-negative, case–control design study assessed bivalent COVID-19 vaccine effectiveness (VE) against symptomatic infection.</p>\n </section>\n \n <section>\n \n <h3> Results</h3>\n \n <p>VE against symptomatic infection of a bivalent dose between 2 weeks and 1 month after bivalent vaccination ranged from 46% (95% CI: 38%–52%) for those aged ≥ 65 years to 61% (95% CI 41%–75%) for those aged 12–17 years.</p>\n </section>\n \n <section>\n \n <h3> Conclusion</h3>\n \n <p>Bivalent vaccines protected against symptomatic infection. However, effectiveness waned over time, emphasizing the need to stay up to date with COVID-19 vaccination.</p>\n </section>\n </div>","PeriodicalId":13544,"journal":{"name":"Influenza and Other Respiratory Viruses","volume":"18 11","pages":""},"PeriodicalIF":4.3000,"publicationDate":"2024-11-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11550894/pdf/","citationCount":"0","resultStr":"{\"title\":\"Effectiveness of Bivalent mRNA Vaccines in Preventing Symptomatic SARS-CoV-2 Infection—Increasing Community Access to Testing Program, United States, January–September 2023\",\"authors\":\"Allison Avrich Ciesla, Josephine Mak, Lauren E. Roper, Katherine E. Fleming-Dutra, Zachary R. Smith, Ryan E. Wiegand, Amadea Britton, Joseph Miller, Ruth Link-Gelles\",\"doi\":\"10.1111/irv.70038\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<div>\\n \\n \\n <section>\\n \\n <h3> Background</h3>\\n \\n <p>On September 2, 2022, bivalent COVID-19 mRNA vaccines, were recommended to address reduced effectiveness of COVID-19 monovalent vaccines during SARS-CoV-2 Omicron variant predominance.</p>\\n </section>\\n \\n <section>\\n \\n <h3> Methods</h3>\\n \\n <p>Using national pharmacy-based SARS-CoV-2 testing program data from January 15 to September 11, 2023, this test-negative, case–control design study assessed bivalent COVID-19 vaccine effectiveness (VE) against symptomatic infection.</p>\\n </section>\\n \\n <section>\\n \\n <h3> Results</h3>\\n \\n <p>VE against symptomatic infection of a bivalent dose between 2 weeks and 1 month after bivalent vaccination ranged from 46% (95% CI: 38%–52%) for those aged ≥ 65 years to 61% (95% CI 41%–75%) for those aged 12–17 years.</p>\\n </section>\\n \\n <section>\\n \\n <h3> Conclusion</h3>\\n \\n <p>Bivalent vaccines protected against symptomatic infection. However, effectiveness waned over time, emphasizing the need to stay up to date with COVID-19 vaccination.</p>\\n </section>\\n </div>\",\"PeriodicalId\":13544,\"journal\":{\"name\":\"Influenza and Other Respiratory Viruses\",\"volume\":\"18 11\",\"pages\":\"\"},\"PeriodicalIF\":4.3000,\"publicationDate\":\"2024-11-10\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11550894/pdf/\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Influenza and Other Respiratory Viruses\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://onlinelibrary.wiley.com/doi/10.1111/irv.70038\",\"RegionNum\":4,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q1\",\"JCRName\":\"INFECTIOUS DISEASES\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Influenza and Other Respiratory Viruses","FirstCategoryId":"3","ListUrlMain":"https://onlinelibrary.wiley.com/doi/10.1111/irv.70038","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"INFECTIOUS DISEASES","Score":null,"Total":0}
Effectiveness of Bivalent mRNA Vaccines in Preventing Symptomatic SARS-CoV-2 Infection—Increasing Community Access to Testing Program, United States, January–September 2023
Background
On September 2, 2022, bivalent COVID-19 mRNA vaccines, were recommended to address reduced effectiveness of COVID-19 monovalent vaccines during SARS-CoV-2 Omicron variant predominance.
Methods
Using national pharmacy-based SARS-CoV-2 testing program data from January 15 to September 11, 2023, this test-negative, case–control design study assessed bivalent COVID-19 vaccine effectiveness (VE) against symptomatic infection.
Results
VE against symptomatic infection of a bivalent dose between 2 weeks and 1 month after bivalent vaccination ranged from 46% (95% CI: 38%–52%) for those aged ≥ 65 years to 61% (95% CI 41%–75%) for those aged 12–17 years.
Conclusion
Bivalent vaccines protected against symptomatic infection. However, effectiveness waned over time, emphasizing the need to stay up to date with COVID-19 vaccination.
期刊介绍:
Influenza and Other Respiratory Viruses is the official journal of the International Society of Influenza and Other Respiratory Virus Diseases - an independent scientific professional society - dedicated to promoting the prevention, detection, treatment, and control of influenza and other respiratory virus diseases.
Influenza and Other Respiratory Viruses is an Open Access journal. Copyright on any research article published by Influenza and Other Respiratory Viruses is retained by the author(s). Authors grant Wiley a license to publish the article and identify itself as the original publisher. Authors also grant any third party the right to use the article freely as long as its integrity is maintained and its original authors, citation details and publisher are identified.